Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel

Yilmaz, Akin; Alp, Ebru; ÖNEN, HACER; Menevse, Sevda

doi:10.5114/wo.2016.58498

Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel

Atıf İçin Kopyala

Yilmaz A., Alp E., ÖNEN H. İ., Menevse S.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, cilt.20, sa.1, ss.28-32, 2016 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 20 Sayı: 1
Basım Tarihi: 2016
Doi Numarası: 10.5114/wo.2016.58498
Dergi Adı: WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
Sayfa Sayıları: ss.28-32
Gazi Üniversitesi Adresli: Evet

Özet

Aim of the study: Cervical cancer is the second most common malignancy in women worldwide. Everolimus displays direct effects on growth and proliferation of cancer cells via inhibition of mammalian target of rapamycin (mTOR) protein, which is known to be associated with drug resistance. In this study, we aimed to investigate the effects of everolimus, gemcitabine, and paclitaxel in terms of cell viability and mRNA expression levels of GRP78, CCND1, CASP2, and BCL2 genes.